Drug Formulary Update, October 2017
Medicare

Updates to the HealthPartners Medicare Drug Formulary are listed below.

Please see www.healthpartners.com/formularies for details.

HealthPartners Medicare

Drug Name	Current Status	New Status	Effective Date	Comments
Abaloparatide (TYMLOS)	NF	T5 PA	10/1/2017	See web for PA criteria.
ANORO (umeclidinium/ vilanterol) inhaler	T3 PA	T3	1/1/2018	
Crisaborole (EUCRISA) ointment	NF	T5 PA	7/1/2017	See web for PA criteria.
Dabigatran (PRADAXA)	T3	T3 PA	1/1/2018	Prior authorization coverage criteria have been added. Pradaxa will be reserved for patients with an inadequate response or medical contra-indications to preferred anticoagulants (Xarelto and Eliquis).
Deutetrabenazine (AUSTEDO)	NF	T5 PA	10/1/2017	See web for PA criteria.
Dupilumab (DUPIXENT)	NF	T5 PA	7/1/2017	See web for PA criteria.
Erythromycin		NF	1/1/2018	Erythromycin has been removed from the formulary. Alternatives include azithromycin.
Icosapent ethyl (VASCEPA)	T3	NF	1/1/2018	Alternatives include omerga-3-acid ethyl esters (Lovaza generic).
Insulin glargine (BASAGLAR)	NF	T3	1/1/2018	Basaglar has been added to formulary, and will replace Lantus and Toujeo.
Insulin glargine (LANTUS and TOUJEO)	T3	NF	1/1/2018	Lantus and Toujeo are being removed from the formulary. Basaglar will be preferred.
Lidocaine ointment	T2	NF	1/1/2018	
Lopinavir/ ritonavir (KALETRA generic) solution	NF	T2	2/24/2017	
Loteprednol (ALREX) ophthalmic	T4	NF	1/1/2018	
Maraviroc (SELZENTRY)	NF	T5	2/8/2017	
Midostaurin (RYDAPT)	NF	T5 PA	5/13/2017	See web for PA criteria.

Formulary Abbreviations: T1 =Preferred Generic, T2 = Generic, T3 = Preferred Brand, T4 = Non-Preferred Brand, T5 = Specialty, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, SP = Specialty Drug, QL = Quantity Limit

Drug Name	Current Status	New Status	Effective Date	Comments
Naproxen sodium	T1	NF	1/1/2018	Naproxen sodium (generic Anaprox) has been removed from the formulary.
Neratinib (NERLYNX)	NF	T5 PA	7/29/2017	See web for PA criteria.
Olmesartan	NF	T2	10/1/2017	
Olmesartan/ HCTZ	NF	T2	10/1/2017	
Olopatadine (PATADAY and PAZEO) ophthalmic	T4	NF	1/1/2018	Ketotifen OTC (e.g. Alaway, Zaditor) is an alternative, and formulary alternatives include azelastine (Optivar generic) and olopatadine (Patanol generic).
Ribavirin (RIBASPHERE) dose pack	NF	T5	2/15/2017	
Rifapentine (PRIFTIN)	T3 PA	T4	1/1/2018	
Solifenacin (VESICARE)	T3	NF	1/1/2018	Oxybutynin, tolterodine (Detrol and Detrol LA generic), trospium (Sanctura IR generic), and mirabegron (Myrbetriq) remain available on formulary.
STIOLTO (tiotropium/ olodaterol) inhaler	T3	NF	1/1/2018	Stiolto is being removed from the formulary. Incruse and Anoro will be preferred.
Telotristat (XERMELO)	NF	T5 PA	7/1/2017	See web for PA criteria.
Tiotropium (SPIRIVA) inhaler	T3	NF	1/1/2018	Spiriva is being removed from the formulary. Incruse and Anoro will be preferred.
Tobramycin/ loteprednol (ZYLET) ophthalmic	T4	NF	1/1/2018	
Tolmetin	T2	NF	1/1/2018	
Umeclidinium (INCRUSE) inhaler	NF	T3	1/1/2018	
Valbenazine (INGREZZA)	NF	T5 PA	10/1/2017	See web for PA criteria.

Formulary Abbreviations: T1 =Preferred Generic, T2 = Generic, T3 = Preferred Brand,
T4 = Non-Preferred Brand, T5 = Specialty, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy,
SP = Specialty Drug, QL = Quantity Limit

HealthPartners UnityPoint Health

Drug Name	Effective Date	Current Status	New Status	Comments
Abaloparatide (TYMLOS)	NF	T5 PA	10/1/2017	See web for PA criteria.
ANORO (umeclidinium/ vilanterol) inhaler	T3 PA	T3	1/1/2018	
Crisaborole (EUCRISA) ointment	NF	T5 PA	7/1/2017	See web for PA criteria.
Dabigatran (PRADAXA)	T3	T3 PA	1/1/2018	
Deutetrabenazine (AUSTEDO)	NF	T5 PA	10/1/2017	See web for PA criteria.
Dupilumab (DUPIXENT)	NF	T5 PA	7/1/2017	See web for PA criteria.
Erythromycin	T4	NF	1/1/2018	
Icosapent ethyl (VASCEPA)	T3	NF	1/1/2018	
Insulin glargine (BASAGLAR)	NF	T3	1/1/2018	Basaglar has been added to formulary, and will replace Lantus and Toujeo.
Insulin glargine (LANTUS and TOUJEO)	T3	NF	1/1/2018	Lantus and Toujeo are being removed from the formulary. Basaglar will be preferred.
Lidocaine ointment	T4	NF	1/1/2018	Lidocaine ointment has been removed from the formulary.
Lopinavir/ ritonavir (KALETRA generic) solution	NF	T2	2/24/2017	
Loteprednol (ALREX) ophthalmic	T4	NF	1/1/2018	
Maraviroc (SELZENTRY)	NF	T5	2/8/2017	
Midostaurin (RYDAPT)	NF	T5 PA	5/13/2017	See web for PA criteria.
Naproxen sodium	T3	NF	1/1/2018	Naproxen sodium (generic Anaprox) has been removed from the formulary.
Neratinib (NERLYNX)	NF	T5 PA	7/29/2017	
Olmesartan	NF	T4	10/1/2017	
Olmesartan/ HCTZ	NF	T4	10/1/2017	
Olopatadine (PATADAY and PAZEO) ophthalmic	T4	NF	1/1/2018	
Ribavirin (RIBASPHERE) dose pack	NF	T5	2/15/2017	
Rifapentine (PRIFTIN)	T3 PA	T4	1/1/2018	
Solifenacin (VESICARE)	T3	NF	1/1/2018	

Formulary Abbreviations: T1 =Preferred Generic, T2 = Generic, T3 = Preferred Brand,
T4 = Non-Preferred Brand, T5 = Specialty, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy,
SP = Specialty Drug, QL = Quantity Limit

Drug Name	Effective Date	Current Status	New Status	Comments
STIOLTO (tiotropium/ olodaterol) inhaler	T3	NF	1/1/2018	Stiolto is being removed from the formulary. Incruse & Anoro will be preferred.
Telotristat (XERMELO)	NF	T5 PA	7/1/2017	See web for PA criteria.
Tiotropium (SPIRIVA) inhaler	T3	NF	1/1/2018	Spiriva is being removed from the formulary. Incruse & Anoro will be preferred.
Tobramycin/ loteprednol (ZYLET) ophthalmic	T4	NF	1/1/2018	
Tolmetin	T4	NF	1/1/2018	
Umeclidinium (INCRUSE) inhaler	NF	T3	1/1/2018	
Valbenazine (INGREZZA)	NF	T5 PA	10/1/2017	See web for PA criteria.